Dr. Safi Bahcall is an Angel Investor. He was the President and Chief Executive Officer at Synta. He is also the co- founder of Synta. Dr. Bahcall has led Synta from inception through multiple acquisitions, financings, an initial public offering, and the establishment of integrated, multi-product drug discovery and development organization. Prior to founding Synta, Dr. Bahcall was a consultant at McKinsey & Company advising investment banks and pharmaceutical companies on strategy, technology, and operations. Dr. Bahcall also co-founded a drug discovery company focused on novel ion channel research, now part of Synta. Dr. Bahcall received his B.A. summa cum laude in Physics from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral fellow in condensed matter physics at U.C. Berkeley. In 2008, Dr. Bahcall was named Ernst & Young New England Biotechnology/Pharmaceutical Entrepreneur of the Year. He is currently a member of a working group on the future of the U.S. science and technology research enterprise, which consults with the President's Council of Advisers on Science and Technology (PCAST).